Delivery Order SPE2DR25D2014-SPE2DR26FZ79Z
Award Date 11/24/25
Potential Completion Date 11/25/25
Potential Value $5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $47,790.73 delivery order to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials, a biosimilar to rituximab used in cancer and rheumatologic disease treatment. This firm fixed-price, non-set-aside contract is scheduled for completion by December 8, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,830.91 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on November 13, 2025, with completion by November 14, 2025. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $4,950.90 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on October 29, 2025, with completion expected by October 30, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ruxience 500 mg/50 ml vials valued at $5,969.24 under a firm fixed-price contract type. Ruxience is a biosimilar to rituximab, used in treating various cancers and autoimmune conditions. The delivery order carries an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This award represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,939.51 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 ml vials on December 15, 2025, with completion scheduled for December 16, 2025. This competitively awarded, firm fixed-price order represents a continuation of the company's substantial pharmaceutical supply relationship with DLA. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $15,015.87 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in treating various cancers and autoimmune conditions,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $11,951.84 for RUXIENCE 500 mg/50 ml vials on August 19, 2025, with completion scheduled for August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used in the treatment of various cancers...
- The Defense Logistics Agency awarded a delivery order valued at $1,956.88 to AmerisourceBergen Drug Corp for RUXIENCE 500 mg/50 mL vials on August 4, 2025, with completion expected by August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. RUXIENCE is a biosimilar to rituximab used for treating various cancers and autoimmune conditions,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials, a biosimilar monoclonal antibody used in oncology and immunology treatment regimens. This competitively awarded, non-set-aside contract carries a ceiling value of $3,465.55 and was executed on January 5, 2026, with an ultimate completion date of January 6, 2026. The contract operates under firm fixed pricing terms and represents a single delivery order...
- The Defense Logistics Agency awarded a $10,908.55 firm fixed price delivery order to Amerisourcebergen Drug Corporation for Ruxience 500 MG/50 ML vials. Under this order, Amerisourcebergen will deliver 50 mL vials of Ruxience, a biosimilar to Rituxan used to treat certain types of cancer and autoimmune disorders, to a facility in Conshohocken, Pennsylvania by August 31, 2023. As a major component of the Department of Defense that manages global logistics operations for the military services, the...